Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ Other Oncology — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%
Eli Lilly logo
LLYOther oncology — Revenue
$966M+22.4%
Pfizer logo
PFEAll other Oncology — Revenues:
$376M-0.3%
BillionToOne, Inc. logo
BLLNOncology — Revenue
$10.72M+392%
Lantheus Holdings logo
LNTHOncology — Revenue
$240.92M-6.5%
Eli Lilly logo
LLYOncology — Revenue
$2.27B+16.4%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other oncology — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's other oncology — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported other oncology — sales to customers (note 9) of $192M in Q1 2026.
How has Johnson & Johnson's other oncology — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's other oncology — sales to customers (note 9) decreased by 10.3% year-over-year, from $214M to $192M.
What is the long-term trend for Johnson & Johnson's other oncology — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's other oncology — sales to customers (note 9) has grown at a -3.1% compound annual growth rate (CAGR), from $568M to $501M.
What does other oncology — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of oncology pharmaceutical products categorized as 'Other Oncology' within the company's segment reporting. It captures the financial performance of specialized cancer therapies that fall outside of the company's primary or lead oncology product franchises. This figure is critical for assessing the diversification and growth potential of the company's broader oncology portfolio.